Pfizer CFO Dave Denton on Oncology, Obesity, and Pfizer’s Next Growth Cycle
Inside the ICE House
•
32m
Pfizer CFO Dave Denton goes Inside the ICE House to discuss how the company is navigating its post‑COVID transition and positioning itself for a return to sustainable growth later this decade. He details Pfizer’s major strategic investments in oncology and metabolic health, including the Seagen and Metsera deals, and explains how proven platforms, global scale, and financial discipline are central to those moves. Denton also shares how execution, patient‑centric innovation, and emerging technologies like AI are shaping the next chapter of Pfizer’s growth story.
Up Next in Inside the ICE House
-
Not Impossible Labs CEO Mick Ebeling ...
Innovation is a spark that ignites progress and transforms the world we live in. It empowers us to tackle the toughest challenges from combating climate change to revolutionizing healthcare and driving economic opportunity. Innovation took center stage at ICE Experience 2025 as Mick Ebeling, Foun...
-
Global X ETFs Pedro Palandrani on the...
Global X ETFs’ Pedro Palandrani goes Inside the ICE House to discuss the launch of the Global X NYSE 100 ETF and how it redefines innovation investing. He explains how the fund expands beyond traditional tech classifications to capture tech-enabled leaders across multiple sectors and exchanges us...
-
Enerpac President & CEO Paul Sternlie...
Reliability is the backbone of industrial operations, and durable, high-quality tools are essential to minimizing costly downtime. For over a century, Enerpac Tool Group (NYSE: EPAC) has been at the forefront of innovation, delivering technically superior solutions that are safe, long-lasting, an...
